Table 4 Heterogeneity assessment in clinical studies of immune checkpoint inhibitors. The Akaike Information Criterion (AIC) and the percentage of heterogeneity explained by each modifier (R2) are shown for each model
Modifier | Log-OS HRs | Log-PFS HRs | ||
|---|---|---|---|---|
AIC | R2 | AIC | R2 | |
Cancer type | -8.134 | 46% | 51.85 | 37% |
Therapeutic agent(s) | 22.17 | 0% | 65.08 | 12% |
Type of masking | -30.38 | 27% | 45.8 | 46% |